Unassociated Document
 
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934

Date of Report: (Date of earliest event reported): September 3, 2009

CLEVELAND BIOLABS, INC.
(Exact name of registrant as specified in its charter)
 
Delaware
  
001-32954
  
20-0077155
(State or other jurisdiction
of incorporation or organization)
  
(Commission File Number)
  
(I.R.S. Employer
Identification Number)

73 High Street, Buffalo, New York 14203
(Address of principal executive offices)

Registrant’s telephone number, including area code: (716) 849-6810

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2.):

¨
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

¨
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

¨
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

¨
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
 
 
 
 
 
Item 1.01
Entry into a Material Definitive Agreement

On September 3, 2009, Cleveland BioLabs, Inc. (the “Company”) entered into a license agreement with Zhejiang Hisun Pharmaceutical Co., Ltd. to develop and commercialize Protectan CBLB612 in the People’s Republic of China, Taiwan, Hong Kong, and Macau. A copy of the agreement is attached hereto as Exhibit 10.1 and is incorporated herein by reference. A copy of the press release announcing the agreement is attached hereto as Exhibit 99.1.
 
Item 9.01
Financial Statements and Exhibits

(d)   Exhibits

Exhibit No.
  
Exhibit
10.1
  
License Agreement between Cleveland BioLabs, Inc. and Zhejiang Hisun Pharmaceutical Co., Ltd , dated September 3, 2009
     
99.1
  
Press Release dated September 9, 2009
 
 
2
 
 
SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
 
 
CLEVELAND BIOLABS, INC
     
     
Date: September 9, 2009
By:  
/s/  Michael Fonstein
 
Michael Fonstein
 
President and Chief Executive Officer
 
 
3
 
 
EXHIBIT INDEX

Exhibit No.
  
Exhibit
10.1
  
License Agreement between Cleveland BioLabs, Inc. and Zhejiang Hisun Pharmaceutical Co., Ltd , dated  September 3, 2009
     
99.1
  
Press Release dated September 9, 2009
 
 
4